SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN

Sarah Mohammed Abed; Nagham Mahmood Aljamali

doi:10.31838/ecb/2022.11.11.006

2023, Vol: 12, Issue: 1

12/1Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

« Previous Article

Research Article

ECB. 2022; 11(11): 46-63

doi: 10.31838/ecb/2022.11.11.006

SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN

Sarah Mohammed Abed, Nagham Mahmood Aljamali.

Abstract
Innovative Macrocyclic Formazan Compounds as a bio-compounds were generated and advanced globally designed for the initial stage by investigator Professor. Dr. Nagham M. Aljamali in 2019) via more than five steps of reaction with various catalyst like (Sodium- alkali 5% ,Pipridine, trimethyl amine , etc.). For that reason, these invented compounds act one of the advanced and new assemblies which have a deficiency of references and researches which lead us to prepare and create a restraint of these innovated compounds and studied by abundant requests in future literatures represented by biological, pharmaceutical, nano, antimicrobial studies, also as anticancer agents ,Normal Formazan was first synthesis over a century ago, but still attention of chemists ,biologists ,technologists and other specialists and here in this research. A numeral of applied spectroscopic studies have been used to revel their chemical assemblies which delivered to sturdy indications of their chemical assemblies through various technical devices like (FT IR-Ranges, 1H.NMR-Ranges, 13C.NMR-Ranges)., Also anticancer study

Key words: Macrocyclic Formazan, Normal Formazan ,Schiff base, Azo, Anil, innovative compounds, breast cancer.

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Sarah Mohammed Abed Articles by Nagham Mahmood Aljamali
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Abed SM, Aljamali NM. SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN. ECB. 2022; 11(11): 46-63. doi:10.31838/ecb/2022.11.11.006

Web Style

Abed SM, Aljamali NM. SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN. https://www.eurchembull.com/?mno=131725 [Access: January 21, 2023]. doi:10.31838/ecb/2022.11.11.006

AMA (American Medical Association) Style

Abed SM, Aljamali NM. SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN. ECB. 2022; 11(11): 46-63. doi:10.31838/ecb/2022.11.11.006

Vancouver/ICMJE Style

Abed SM, Aljamali NM. SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN. ECB. (2022), [cited January 21, 2023]; 11(11): 46-63. doi:10.31838/ecb/2022.11.11.006

Harvard Style

Abed, S. M. & Aljamali, . N. M. (2022) SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN. ECB, 11 (11), 46-63. doi:10.31838/ecb/2022.11.11.006

Turabian Style

Abed, Sarah Mohammed, and Nagham Mahmood Aljamali. 2022. SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN. European Chemical Bulletin, 11 (11), 46-63. doi:10.31838/ecb/2022.11.11.006

Chicago Style

Abed, Sarah Mohammed, and Nagham Mahmood Aljamali. "SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN." European Chemical Bulletin 11 (2022), 46-63. doi:10.31838/ecb/2022.11.11.006

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Abed, S. M. & Aljamali, . N. M. (2022) SYNTHESIS, INVESTIGATION AND ANTICANCER EVALUATION OF NOVEL MACROCYCLIC FORMAZAN AND LINEAR FORMAZAN. European Chemical Bulletin, 11 (11), 46-63. doi:10.31838/ecb/2022.11.11.006

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Author's Rights and Obligations Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Privacy Policy Corrections, Retractions & Expressions of Concern Self-Archiving Policies Digital Archiving & Preservation Policies Statement of Informed Consent Advertising Policy Terms of Use License Information

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access. The articles in European Chemical Bulletin are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

Copyright � 2023 European Chemical Bulletin All Rights Reserved. Subject to change without notice from or liability to European Chemical Bulletin. For best results, please use Internet Explorer or Google Chrome	Contact Information European Chemical Bulletin Budapest, Near Széchenyi István tér, 1051 Hungary Email : editor@eurchembull.com

Contact Information

How to cite this article